GLP-1 analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-11 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
容器与密封系统同样参与稳定性表现。硅油涂层、胶塞材质与顶空氧含量可能改变聚集速率与氧化水平。分析结果因此需要在完整包装形式下评估，而不能仅凭原料药数据推断。法规文件通常要求同时提交批次数据与代表性容器中的稳定性趋势。
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
Open fuel cycle: the cycle starts with the mining of uranium, goes through the fuel fabrication and ends with the direct disposal of the spent fuel. Closed fuel cycle: the spent fuel stored for a long time can be safely handled and it undergoes reprocessing in order to recover and recycle a large amount of it.
In 2010, due to a rise in foreign competition, Ajinomoto began restructuring to focus on several of its products while divesting others. The company divested its Calpis beverage unit in Japan in 2012, the Ajinomoto Sweetener Company (France) in October 2015, and Amoy Food (China) in November 2018. Ajinomoto decided to focus on its food and biomedical divisions, and acquired the contract manufacturing organization Althea Technologies (US) in 2013, the frozen food company Windsor Quality Holdings, Inc. (US) in November 2014, and the frozen food company Lavelli・Terrell・Smile (France) in November 2017. In April 2016, Ajinomoto merged its pharmaceutical division with Eisai, launching EA Pharma in Japan. In October 2017, Ajinomoto introduced a "Global Brand Logo" for use throughout the Ajinomoto group. In December 2017, Ajinomoto announced it had begun construction to expand its Kawasaki Plant, along with the construction of a new R&D building. In October 2018, Ajinomoto Althea (US) and OmniChem (Belgium) merged to form Ajinomoto Bio-Pharma Services, but in April 2025, all of Althea shares were transferred to Packaging Coordinators Inc. In April 2020, the Ajinomoto Group Nutrient Profiling System for Product, which has been developed as a method to scientifically estimate the nutritive value of products such as powdered soup and frozen foods, was introduced globally to about 500 kinds of group products in seven countries. In August, Ajinomoto announced its participation in the international environment initiative RE100 for renewable energy.
Silver nitrate is an inorganic compound with chemical formula AgNO3. It is a colorless solid that is a precursor to many other silver compounds. Silver nitrate is highly soluble in water but is poorly soluble in most organic solvents, except acetonitrile (111.8 g/100 g, 25 °C). Silver nitrate is the least expensive salt of silver; it offers several other advantages as well. It is non-hygroscopic (in contrast to silver fluoroborate and silver perchlorate). In addition, it is relatively stable to light, and it dissolves in numerous solvents, including water. The nitrate can be easily replaced by other ligands.
Sources: en.wikipedia.org
Tetramethylurea (TMU) is the organic compound with the formula (Me2N)2CO. It is a substituted urea. This colorless liquid is used as an aprotic-polar solvent, especially for aromatic compounds and is used e. g. for Grignard reagents. TMU has a mild aromatic odor and, unlike other compounds of urea, is a colorless liquid.
=== MDP-collagen interactions === The binding interaction between collagen and MDP was studied by saturation transfer difference (STD) NMR spectroscopy. The STD results imply that MDP has a relatively stable interaction with the collagen, because of the hydrophobic interactions between the hydrophobic MDP moieties and the hydrophobic collagen surface.
=== Texas research initiative === In 2025, the state of Texas allocated $50 million to fund clinical research on ibogaine, aiming to develop a U.S. Food and Drug Administration-approved treatment for opioid use disorder, co-occurring substance use disorders, and other ibogaine-responsive conditions. The initiative, supported by former Governor Rick Perry, established a consortium of universities, hospitals, and drug developers, with the goal of positioning Texas as a leading center for psychedelic medicine research.
Sources: en.wikipedia.org
=== Return to Prague === In November 1945, Smolková-Keulemansová returned to Prague to continue her studies. She completed grammar school and realized that the biggest struggle in her supplementary exams was chemistry, so she began to study chemistry at Charles University in Prague, leading to her lifelong devotion and love for the subject. She graduated from the Faculty of Natural Sciences at Charles University in 1952.
== Structure == Human gamma-actin is 41.8 kDa in molecular weight and 375 amino acids in length. Actins are highly conserved proteins that are involved in various types of cell motility, and maintenance of the cytoskeleton. In vertebrates, three main groups of actin paralogs, alpha, beta, and gamma, have been identified. The alpha actins are found in muscle tissues and are a major constituent of the sarcomere contractile apparatus. The beta and gamma actins co-exist in most cell types as components of the cytoskeleton, and as mediators of internal cell motility. Actin, gamma 1, encoded by this gene, is found in non-muscle cells in the cytoplasm, and in muscle cells at costamere structures, or transverse points of cell-cell adhesion that run perpendicular to the long axis of myocytes.
1st choice: Surgical amputation - break - prosthesis 2nd choice: Surgical amputation - transplantation of other tissue - plastic reconstruction. 3rd choice: Replantation - reconnection - revascularisation of amputated limb, by microscope (after 1969) 4th choice: Transplantation of cadaveric hand (after 2000)
Chloroplasts have their own ribosomes, which they use to synthesize a small fraction of their proteins. Chloroplast ribosomes are about two-thirds the size of cytoplasmic ribosomes (around 17 nm vs 25 nm). They take mRNAs transcribed from the chloroplast DNA and translate them into protein. While similar to bacterial ribosomes, chloroplast translation is more complex than in bacteria, so chloroplast ribosomes include some chloroplast-unique features. Small subunit ribosomal RNAs in several Chlorophyta and euglenid chloroplasts lack motifs for Shine-Dalgarno sequence recognition, which is considered essential for translation initiation in most chloroplasts and prokaryotes. Such loss is also rarely observed in other plastids and prokaryotes. An additional 4.5S rRNA with homology to the 3' tail of 23S is found in "higher" plants.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.